In a seed round led by Inflection Point Ventures (IPV) and Anthill Ventures, Bengaluru-based medical technology startup Cureous Labs has raised Rs 1.66 crore.
The first batch of its flagship product, Eturnal, will be manufactured with the proceeds. Additionally, inventory will be built, the sales and business development team will be expanded, the first disinfection center will be launched, and product safety testing and certifications will be finished.
Additionally, Cureous Labs intends to broaden its offering for Indian B2B clients.
Cureous Labs, which was founded by Asish Mohandas, creates automated patient repositioning systems to reduce pressure injuries and increase caregiver productivity. The device, which costs one-fifth of international alternatives, is intended for use in home care, rehabilitation facilities, and hospitals.
The company claims that it has already recorded more than 14,000 automated patient turns and more than 30,000 hours of use.
Market research estimates that the global market for care for elderly and bedridden patients is worth $277 billion. The entire market that can be reached in India is worth $8.34 billion.
